The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson's Disease
Abstract
Tetracycline-derived compounds with anti-inflammatory properties have demonstrated neuroprotective potential in preclinical models of Parkinson’s disease. In this study, we investigated the efficacy of DDOX (4-dedimethylamino 12a-deoxydoxycycline), a novel non-antibiotic tetracycline derivative. We used an intrastriatal unilateral 6-hydroxydopamine (6-OHDA) lesion paradigm in rats, which leads to partial nigrostriatal dopaminergic denervation. Our goal was to assess whether DDOX could preserve nigrostriatal dopaminergic integrity, reduce lesion-associated glial responses in the striatum, and improve motor function. Daily administration of DDOX (20 mg/kg, subcutaneously), beginning five days prior to lesion and continuing for fifteen days post-lesion, significantly attenuated the loss of dopaminergic terminals in the dorsal striatum and that of dopaminergic cell bodies in the ventral substantia nigra, as indicated by tyrosine hydroxylase (TH) immunostaining analysis. DDOX also markedly suppressed lesion-induced glial responses in the striatum. Behavioral assessments revealed that DDOX preserved motor performance, as evidenced by improved forelimb use (stepping test), maintained coordination and balance (rotarod), and maintained spontaneous locomotion (open field - actimeter). Additionally, DDOX significantly diminished amphetamine-induced rotational asymmetry, suggesting preservation of dopaminergic tone. Notably, the extent of functional recovery exceeded the degree of TH-immunoreactive nerve terminal preservation, indicating that DDOX’s benefits may extend beyond dopaminergic neuroprotection. Further studies are warranted to elucidate the underlying mechanisms of these effects and confirm DDOX’s efficacy in other Parkinson’s disease models.
Related
- Ringer Loss in Uncovers Mitochondrial Complex I Deficits Relevant to Human Parkinson's Disease
- Modelling prodromal Parkinson's disease- gastrointestinal pathology and early motor deficits in mice after transient rotenone exposure
- A Tissue-Targeted Immunotherapy Protects Against Recurrent Ocular Herpes Infection and Disease, and Alleviates the Associated Cognitive, Behavioral, and Social Deficits in a 'Humanized' HLA Transgenic Mouse Model of UVB-Induced Reactivation
- Neuroprotective activity of sub-anesthetic ketamine in a preclinical model of Parkinson's disease is not blocked by antagonizing brain-derived neurotrophic factor signaling
- Sex- and age-dependent control of dopamine function by LRRK2, and rapid reversal of dopamine release deficits in the LRRK2-G2019S knock-in mouse model of Parkinson's Disease.
BibTeX
@article{borges2026small,
title = {{The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson's Disease}},
author = {Lorena Borges and Glauce Crivelaro Do Nascimento and Laurent Ferrié and Rita Raisman-Vozari and Bruno Figadère and Patrick Pierre Michel and Elaine Del-Bel},
journal = {Neurotoxicity Research},
year = {2026},
month = oct,
doi = {10.1007/s12640-025-00772-0},
url = {https://hal.science/hal-05775943v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson's Disease
AU - Lorena Borges
AU - Glauce Crivelaro Do Nascimento
AU - Laurent Ferrié
AU - Rita Raisman-Vozari
AU - Bruno Figadère
AU - Patrick Pierre Michel
AU - Elaine Del-Bel
PY - 2026
DA - 2026/10/02
JO - Neurotoxicity Research
DO - 10.1007/s12640-025-00772-0
UR - https://hal.science/hal-05775943v1
AB - Tetracycline-derived compounds with anti-inflammatory properties have demonstrated neuroprotective potential in preclinical models of Parkinson’s disease. In this study, we investigated the efficacy of DDOX (4-dedimethylamino 12a-deoxydoxycycline), a novel non-antibiotic tetracycline derivative. We used an intrastriatal unilateral 6-hydroxydopamine (6-OHDA) lesion paradigm in rats, which leads to partial nigrostriatal dopaminergic denervation. Our goal was to assess whether DDOX could preserve nigrostriatal dopaminergic integrity, reduce lesion-associated glial responses in the striatum, and improve motor function. Daily administration of DDOX (20 mg/kg, subcutaneously), beginning five days prior to lesion and continuing for fifteen days post-lesion, significantly attenuated the loss of dopaminergic terminals in the dorsal striatum and that of dopaminergic cell bodies in the ventral substantia nigra, as indicated by tyrosine hydroxylase (TH) immunostaining analysis. DDOX also markedly suppressed lesion-induced glial responses in the striatum. Behavioral assessments revealed that DDOX preserved motor performance, as evidenced by improved forelimb use (stepping test), maintained coordination and balance (rotarod), and maintained spontaneous locomotion (open field - actimeter). Additionally, DDOX significantly diminished amphetamine-induced rotational asymmetry, suggesting preservation of dopaminergic tone. Notably, the extent of functional recovery exceeded the degree of TH-immunoreactive nerve terminal preservation, indicating that DDOX’s benefits may extend beyond dopaminergic neuroprotection. Further studies are warranted to elucidate the underlying mechanisms of these effects and confirm DDOX’s efficacy in other Parkinson’s disease models.
SN - 1029-8428
ER -